According to a recent study from market research firm Graphical Research, the Europe biodefense market size is projected to reach a valuation US$ 6.3 Bn by 2028.
The rising prevalence of infectious diseases is driving Europe biodefense market growth. Since the World Health Organization (WHO) labeled the COVID-19 outbreak a pandemic in March 2020, the virus has caused more than 2.5 million deaths worldwide, as per news-medical.net. Not just that, over the last two decades, several diseases such as swine flu, bird flu, and other viral diseases have become localized pandemics. Even seasonal flus have become more severe during the previous two decades. As a result, bio attenuation is necessary not just for COVID-19 protection, but also for general viral protection over the next 5 to 10 years.
The following three trends are likely to have a strong impact on the market over 2022-2028:
Efficient vaccination has proven its importance in the past two difficult years of the pandemic. Many experts believe that without them, natural herd immunity would not have been able to return society to its original state, resulting in high mortality. Many health agencies, including the WHO, have echoed this sentiment. In the absence of vaccinations, rigorous behavioral controls would have to be maintained for the foreseeable future.
As of March 2021, approximately 300 million vaccination doses had been delivered globally, as per news-medical.net. Thanks to various private & public investments in vaccine development, Europe biodefense industry share from the vaccines segment accounted for $2.5 billion revenue in 2021. Vaccinations for diseases such as HPV (human papillomavirus), Hib illness (Haemophilus influenzae type b), and hepatitis B are widely available, making it easier for governments to curb the spread of these diseases.
Due to the increasing use of various detection equipment such as IDs throughout the region, Europe biodefense industry share from biothreat detection devices accounted for approximately 36% of the total market in 2021. A biological agent identifier is a device that accurately detects biological agents. Botulinum toxin, smallpox, ricin, anthrax, black plague, and tularemia are examples of common biothreat agents recognized by identification. It has been demonstrated that these systems can detect SARS-CoV-2 in the air.
Recently, IVP debuted their technology which claims to kill COVID-19 in the United States. The biodefense system employs very porous folded nickel foam that is heated to high enough temperatures to destroy SARS-CoV-2. This, in conjunction with their HEPA filters and UV-C light, creates a reinforced bio-defense indoor protection system. The filter does not interfere with airflow or emit dangerous ozone.
Because of the rising frequency of infectious illnesses, the U.K. industry size was worth $987 million in 2021. According to the U.K. Government, there were 3,419 suspected and 401 confirmed cases of Lassa fever in Nigeria as of October 24, 2021. To address such biosecurity issues, the regional government is focused on biodefense research & producing an action plan for the Biological Security Strategy, and establishing a dedicated National Centre for Biosecurity, which will serve as a center of knowledge on the whole range of biological threats confronting the U.K.
ANP Technologies, Bavarian Nordic, Bruker Detection, Emergent BioSolutions, Ichor Medical Systems, Inc., New Horizon Diagnostic Corp., and SIGA Technologies are counted amongst the top biodefense companies in Europe. With a view to diversify themselves, industry players are adopting a slew of marketing strategies to attract new customers.
Heat Biologics, Inc., a biopharmaceutical company developing first-in-class immunomodulatory therapies, acquired Elusys Therapeutics, Inc., a developer of obiltoxaximab, treatment for anthrax inhalation, in April 2022. In Europe and the United Kingdom, the medicine is marketed under the brand name Obiltoxaximab SFL.
Source: https://www.graphicalresearch.com/industry-insights/2112/europe-biodefense-market
